• Home
  • A-B index
  • Pharmacological Index
  • Drug Classes
  • Active Ingredients
  • Companies
  • News
  • Profex
    / Taro

    Active Ingredient

    Status in Israel

    Presentation and Status in Health Basket

    Presentation Basket Yarpa Pharmasoft


    30 x 150 mg

    partial basket chart 66471 16380


    30 x 300 mg

    partial basket chart 66472 16375

    Related information


    Initial dose: 150 mg every 8 hours. Increas every 3-4 days to
    300 mg every 12 hours.
    See prescribing information for full details.


    Prophylactic, treatment of ventrical arrhythmia, atrial fibrillation and flutter, PSVT associated with disabled symptoms.


    In patients with uncontrolled congestive heart failure, cardiogenic shock, atrioventricular or intraventricular disorders of impulse generation and/or conduction (e.g. sick sinus node syndrome, atrioventricular block) unless an artificial pacemaker is present, bradycardia, severe hypotension, marked electrolyte imbalance, or known hypersensitivity to the drug. Concomitant use of ritonavir with propafenone is contraindicated.

    Special Precautions

    Can worsen existing arrhythmias or cause new arrhythmias. May cause or worsen congestive heart failure, particularly in patients with preexisting heart failure or decreased left ventricular ejection fraction. Patients with impaired hepatic function. The possibility of agranulocytosis should be considered in any patient who develops unexplained fever and/or decreases in WBC count. Use of any class IC antiarrhythmic drug in patients with structural heart disease may be associated with substantial risk. Use of class I agents in patients with ventricular arrhythmias are limited to those with life-threatening arrhythmias. Patients with a history of congestive heart failure or myocardial dysfunction. Patients should be advised to promptly report fever, sore throat and chills. Impaired hepatic function, renal dysfunction. Patients should be discouraged from ingesting grapefruit juice concomitantly. Patients with asthma/bronchospastic disease. Myasthenia gravis. Sick sinus node syndrome, atrioventricular block, bradycardia, severe hypotension, marked electrolyte imbalance. Pregnancy and lactation: Should be used during pregnancy only when the potential benefits justify the possible risks to the fetus. A decision should be made whether to discontinue nursing or the drug, taking into account the importance of the drug to the woman.

    Side Effects

    The most common adverse effects involve the GI, cardiovascular and central nervous systems and generally are dose related. Discontinuance was required in about 20% of patients in clinical trials. Adverse effects tend to decrease with time and may be attenuated by dosage reduction. Dizziness and/or lightheadedness, fatigue/lethargy, headache, weakness, ataxia, insomnia, anxiety, tremor and drowsiness. Nausea and/or vomiting, dysgeusia, dyspepsia and/or diarrhea, abdominal pain/cramps. Chest pain or angina, palpitations or syncope. Rash and pruritis. Blurred vision. Asthma, increased serum glucose concentration, diabetes mellitus, hypochloremia, hyponatremia, syndrome of inappropriate antidiuretic hormone secretion, nephrotic syndrome, renal failure, nasal congestion, ocular irritation.
    See prescribing information for full details.

    Drug interactions


    Taro Pharmaceutical Industries